Clinical trials: Organoids
Cystic Fibrosis
Organoid Study R334W
In contrary to what is seen in FRT cells, rectal organoids of patients with a R334W mutation do respond to CFTR modulators ivacaftor and lumacaftor.
- Trial name
- NCT04254705
- Testing
- Rectal Biopsy
- Where
- 12 sites in Belgium, France and 3 more
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Gastro-entero-pancreatic Neoplasms
Generation of Organoids of Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic Tract Obtained From Patients Undergoing Surgery
Observational, prospective, feasibility pilot study of the preparation of organoids starting from tumor tissue and surrounding healthy tissue, collected during surgery, performed according to standard clinical practice.
- Trial name
- NCT06519500
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Regina Elena Cancer Institute
Lung Cancer, Non-Small Cell
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to…
- Trial name
- NCT06405230
- Testing
- Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Neoadjuvant Therapy
The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer
This is a prospective multicenter randomized controlled trial study. According to the enrollment criteria, patients with locally advanced rectal cancer who need neoadjuvant therapy before radical surgery were randomly divided…
- Trial name
- NCT05352165
- Testing
- standard long-term therapy, FOLFOX and standard long-term radiotherapy, FOLFIRI and standard long-term radiotherapy
- Volunteers
- 192 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Endometrial Receptivity
Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
Both controlled ovarian stimulation (COS) and frozen embryo transfer has become an integral part of in vitro fertilization (IVF) treatment.
- Trial name
- HormoSenoRec (NCT06280560)
- Testing
- Controlled Ovarian Stimulation + Luteal Phase Support, Hormonal Replacement Therapy programmed artificial cycle, Natural Cycle (NC)
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fundación IVI
Primary Sclerosing Cholangitis, PSC
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
- Conditions
- Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
- Trial name
- NCT04753996
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Ovarian Cancer
The Culture of Ovarian Cancer Organoids and Drug Screening
The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory…
- Trial name
- NCT04768270
- Testing
- no intervention
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Cystic Fibrosis
Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF
CF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of…
- Trial name
- CHOICES (NCT06468527)
- Testing
- Diponecaftor
- Where
- 16 sites in Belgium, France and 7 more
- Volunteers
- 41 people
- Sponsor
- Kors van der Ent
Breast Neoplasms, Male
MALE Mamm Organoids
It is believed that the use of organoids derived from male breast tumors can be of fundamental support for the definition of the molecular mechanisms underlying the onset of the tumor.
- Trial name
- NCT06786663
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer
Developing Breast (Cancer) Organoids
Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups.
- Trial name
- NCT05317221
- Testing
- Not an extra intervention, tissue taken in routine practice will be used.
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht Radiation Oncology
Ovarian Cancer
Individualized Precision Treatment Based on Ovarian Cancer Organoid Model
The research purpose of this study is to use organoid cultured from patients' own ovarian cancer tissues as models, screen potential clinical therapeutic drugs (such as paclitaxel, gemcitabine, etc.) in vitro, formulate…
- Trial name
- NCT05813509
- Testing
- Organoid culture
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Triple Negative Breast Cancer, Organoid
Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
Initially described in 2009 on LGR5 positive stem cells from intestine, organoids correspond to a 3D cell culture that preserves the organization and part of the initial function of the organ from which the cells were derived.
- Trial name
- TRIPLEX (NCT05404321)
- Testing
- Establishment of ex vivo breast cancer organoid models
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Centre Francois Baclesse
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome
In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.
- Trial name
- NCT05400239
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Pancreatic Cancer, Pancreas Adenocarcinoma
Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
We are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.
- Trial name
- NCT03544255
- Testing
- Biopsy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ying Lv
Advanced Leiomyosarcoma
A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy
This study is a prospective single arm multicenter intervention study aimed at evaluating the feasibility of using organoid drug sensitivity results to guide first-line treatment of advanced leiomyosarcoma.
- Trial name
- LMS-HOPE (NCT07405346)
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Soft Tissue Sarcoma, Child
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors
This is a prospective, open-label, single-arm, single-center study designed to evaluate the feasibility of using patient-derived organoid drug sensitivity analysis to guide chemotherapy for pediatric patients with refractory and…
- Trial name
- NCT07528079
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Undifferentiated Carcinoma
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.
- Trial name
- OCAPI (NCT06612827)
- Testing
- organoid etablishment
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Francois Baclesse
Preeclampsia, Pregnancy Loss
Placental Organoids Development: Application in the Study of the Human Reproduction Pathophysiology.
Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis…
- Conditions
- Preeclampsia, Pregnancy Loss, Preterm Birth, Healthy
- Trial name
- PLORG (NCT06893978)
- Testing
- Placenta organoids treatment
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Neoplasm
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Create a living biobank of PDOs from Stage I-III lung cancer patients.
- Trial name
- NCT03655015
- Testing
- Lung Tumor Resection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Colon Cancer, Peritoneal Carcinoma
Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers
Colorectal cancer (CRC) is the 3rd most common cancer in France. Treatment of CRC relies primarily on surgical removal of the primary tumor and chemotherapy is the current standard of care for synchronous metastatic disease.
- Trial name
- I-COMET (NCT06435689)
- Testing
- Sampling
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris